Companies PetMedix

Antibody engineering for animals


Although widely available as therapies in human populations, the use of antibodies in veterinary medicine is in its infancy.

PetMedix is tackling the often challenging development of species-specific therapeutic antibodies, beginning with dogs and cats. PetMedix was acquired by a world leading animal health company, in August 2023 for undisclosed terms which represented the largest ever pre-clinical company sale in animal health.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More